GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Kotak Strategic Situations India Fund Il, managed by Kotak Alternate Asset Managers Ltd, has made an investment  Rs 940 crore ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...